FiercePharma1y
How AbCellera helps partners propel their antibody therapies to the clinic
In the crowded antibodies space, how can small firms move their therapy from idea to candidate status? Carl Hansen, CEO of AbCellera, outlines their u ...
TheStreet.com4y
IPO Launch: AbCellera Biologics Readies $357 Million IPO
Management is headed by co-founder and Chief Executive Officer Carl Hansen, Ph.D., who was previously a scientific co-founder of Precision NanoSystems AbCellera has received at least $88 million ...
Business Wire17d
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
“We are pleased to broaden our AbbVie collaboration and look forward to using AbCellera’s TCE platform to bring novel cancer immunotherapies to patients in need,” said Carl Hansen, Ph.D ...
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and ...
T-Net15d
AbCellera Expands Collaboration with Big Pharma Giant AbbVie to Develop Novel T-Cell Engagers for Oncology
AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell engagers (TCE) in oncology.
Yahoo Finance17d
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
VANCOUVER, British Columbia, January 13, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include ...